Abstract
Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. Prevalence and incidence rates are rising with the advancing population age. A severe complication of untreated AF is thrombus formation in the left atrial appendage with consecutive peripheral thromboembolism. Thus, AF is a major contributor to thromboembolic events, especially in the elderly. Depending on the CHADS2 score for thromboembolic events that takes into account congestive heart failure, hypertension, age, diabetes mellitus and stroke as risk factors, oral anticoagulation therapy with vitamin K antagonists is currently the treatment of choice for the prevention of thromboembolism. However, due to drawbacks of current anticoagulation therapy new substances for oral therapy are currently evaluated in various clinical studies. This article provides an up to date overview of orally active compounds for the future treatment of AF. Emphasis lies on comparison of direct thrombin inhibitors with factor Xa inhibitors that are currently investigated in clinical phase III studies for the treatment of non-valvular AF. The direct thrombin inhibitor dabigatran will be compared with factor Xa inhibitors like rivaroxaban and apixaban. Other promising agents currently investigated in phase II trials such as direct factor Xa inhibitors DU-176b (edoxaban) and YM150, will also be discussed.
Keywords: Atrial fibrillation, anticoagulation, pathophysiology, pharmacology, stroke, thromboembolism, congestive heart failure, hypertension, diabetes mellitus, thrombin inhibitors, thrombin, factor Xa Inhibitors
Current Vascular Pharmacology
Title: Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Volume: 9 Issue: 3
Author(s): Oliver Wolfram, Matthias Hammwoehner, Felix Gramley and Andreas Goette
Affiliation:
Keywords: Atrial fibrillation, anticoagulation, pathophysiology, pharmacology, stroke, thromboembolism, congestive heart failure, hypertension, diabetes mellitus, thrombin inhibitors, thrombin, factor Xa Inhibitors
Abstract: Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. Prevalence and incidence rates are rising with the advancing population age. A severe complication of untreated AF is thrombus formation in the left atrial appendage with consecutive peripheral thromboembolism. Thus, AF is a major contributor to thromboembolic events, especially in the elderly. Depending on the CHADS2 score for thromboembolic events that takes into account congestive heart failure, hypertension, age, diabetes mellitus and stroke as risk factors, oral anticoagulation therapy with vitamin K antagonists is currently the treatment of choice for the prevention of thromboembolism. However, due to drawbacks of current anticoagulation therapy new substances for oral therapy are currently evaluated in various clinical studies. This article provides an up to date overview of orally active compounds for the future treatment of AF. Emphasis lies on comparison of direct thrombin inhibitors with factor Xa inhibitors that are currently investigated in clinical phase III studies for the treatment of non-valvular AF. The direct thrombin inhibitor dabigatran will be compared with factor Xa inhibitors like rivaroxaban and apixaban. Other promising agents currently investigated in phase II trials such as direct factor Xa inhibitors DU-176b (edoxaban) and YM150, will also be discussed.
Export Options
About this article
Cite this article as:
Wolfram Oliver, Hammwoehner Matthias, Gramley Felix and Goette Andreas, Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495512
DOI https://dx.doi.org/10.2174/157016111795495512 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety New Viral Infection COVID-19: Current Status, Challenges and Possible Treatments
Letters in Drug Design & Discovery Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nitric Oxide and Oral Diseases: Can We Talk About It?
Cardiovascular & Hematological Agents in Medicinal Chemistry SARS-CoV-2 & Covid-19: Key-Roles of the ‘Renin-Angiotensin’ System / Vitamin D Impacting Drug and Vaccine Developments
Infectious Disorders - Drug Targets Renin Angiotensin System as a Regulator of Cell Volume. Implications to Myocardial Ischemia
Current Cardiology Reviews Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Effectiveness and Safety of Digoxin on Chronic Heart Failure
Current Pharmaceutical Analysis Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design Crystallization and Preliminary X-Ray Analysis of the Highly Thermostable Sweet Protein Mabinlin II
Protein & Peptide Letters Renin Inhibition as a New Strategy to Combat Cardiovascular Disease
Current Hypertension Reviews Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Proteome Adjustments Post Gradual Hypoxic Stress in Barilius bendelisis: Insights into Adaptive Strategies of a Hill Stream Cyprinid
Current Proteomics Pyridines and Imidazopyridines with Medicinal Significance
Current Topics in Medicinal Chemistry miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry